SEC Form SC 13G/A filed by CRISPR Therapeutics AG (Amendment)

$CRSP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $CRSP alert in real time by email
SC 13G/A 1 ef20021445_sc13ga.htm SC 13G/A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 4)*

CRISPR Therapeutics AG

(Name of Issuer)

Common Shares, nominal value CHF 0.03

(Title of Class of Securities)

H17182108
(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



CUSIP No.

1
NAMES OF REPORTING PERSONS
 
 
Nikko Asset Management Americas, Inc.
 
 
 
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
   
(a)☐
   
(b)
 
 
3
SEC USE ONLY
 
 

 
 
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
USA
 
 
 
 
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5
SOLE VOTING POWER
 
 
0
 
 
 
 
6
SHARED VOTING POWER
 
 
3,050,548
 
 
 
 
7
SOLE DISPOSITIVE POWER
 
 
0
 
 
 
 
8
SHARED DISPOSITIVE POWER
 
 
3,369,762
 
 
 
 
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
3,369,762
 
 
 
 
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
 
 
 
 
 
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
 
4.24%
 
 
 
 
12
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
 
IA
 
 
 
 


Item 1.

 
(a)
Name of Issuer
     


CRISPR Therapeutics AG



 
(b)
Address of Issuer’s Principal Executive Offices
     
   
Baarerstrasse 14
6300 Zug, Switzerland

Item 2.

 
(a)
Name of Person Filing
   
   
Nikko Asset Management Americas, Inc.
   
 
(b)
Address of Principal Business Office or, if none, Residence
   

   
605 Third Avenue, 38th Floor, New York, NY 10158
     
 
(c)
Citizenship
   

    USA
     
 
(d)
Title of Class of Securities
     
   
Common Shares, nominal value CHF 0.03
   
 
(e)
CUSIP Number
     
   
H17182108

Item 3.
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
   
 
 
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
   
 
 
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
   
 
 
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
   
 
 
(e)
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
   
 
 
(f)
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
   
 
 
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
   
 
 
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
   
 
 
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
   
 
 
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
   
 
 
(k)
A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


Item 4.
Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 
(a)
Amount beneficially owned:
       
     
3,369,762
       
 
(b)
Percent of class:
       
     
4.24%
       
 
(c)
Number of shares as to which the person has:
       
   
(i)
Sole power to vote or to direct the vote:
       
     
0
       
   
(ii)
Shared power to vote or to direct the vote:
       
     
3,050,548
       
   
(iii)
Sole power to dispose or to direct the disposition of:
       
     
0
       
   
(iv)
Shared power to dispose or to direct the disposition of:
       
     
3,369,762

Item 5.
Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

Item 6.
Ownership of More than Five Percent on Behalf of Another Person.

See Exhibit A.

Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

See Exhibit A.

Item 8.
Identification and Classification of Members of the Group

Not Applicable.

Item 9.
Notice of Dissolution of Group

Not Applicable.


Item 10.
Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 12, 2024
By:
/s/ Gary L. Beckham


Name: Gary L. Beckham


Title: Chief Compliance Officer

Attention:
Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)


Exhibit A

Pursuant to the instructions in Items 6 and 7 of Schedule 13G, the security being reported on by Nikko Asset Management Americas, Inc., as subsidiary to the parent holding companies listed below, are owned, or may be deemed to be beneficially owned, by its parent holding companies.


1)
Sumitomo Mitsui Trust Holdings Inc.

o
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

o
A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).


2)
Nikko Asset Management Co., Ltd.

o
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

o
A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).



Get the next $CRSP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CRSP

DatePrice TargetRatingAnalyst
2/14/2025$60.00 → $99.00In-line → Outperform
Evercore ISI
2/12/2025$35.00Sell → Hold
TD Cowen
2/3/2025$65.00Buy
H.C. Wainwright
8/6/2024$88.00 → $84.00Buy
Needham
8/2/2024$90.00Buy
Rodman & Renshaw
6/28/2024Neutral
Guggenheim
2/15/2024Peer Perform
Wolfe Research
12/11/2023$30.00Market Perform → Underperform
TD Cowen
More analyst ratings

$CRSP
Press Releases

Fastest customizable press release news feed in the world

See more
  • CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

    -2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated globally for CASGEVY, and more than 50 patients have had cells collected across all regions as of the end of 2024- -Clinical trials ongoing for next-generation CAR T product candidates, CTX112™ and CTX131™, targeting CD19 and CD70 across multiple indications; updates for CTX112 in oncology and autoimmune diseases are expected in mid-2025 with CTX131 updates expected in 2025- -CRISPR Therapeutics and Nkure Thera

    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

    ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 2:00 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation. About CRISPR TherapeuticsSince its inc

    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones

    -Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across several programs- -Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated 2025 milestones. "As we look ahead to 2025, we are in a privileged position with an approved commercial product, a rich pipeline, a strong balance sheet and an o

    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CRSP
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CRSP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CRSP
SEC Filings

See more

$CRSP
Leadership Updates

Live Leadership Updates

See more
  • CRISPR Therapeutics Proposes New Appointment to the Board of Directors

    ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company's annual general meeting to be held this year. "We are excited to welcome Briggs to our Board of Directors," said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics. "His extensive experience in the pharmaceutical industry and expertise in clinical development will be a tremendous asset as we continue to advance our innovative platform and pip

    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

    -Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of disease areas, including his most recent leadership role as the Global Development Therapeutic Area Head of Immunology and Inflammation at Sanofi. In addition, the Company al

    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • CRISPR Therapeutics Announces Transition of Chief Financial Officer

    ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023. He joins CRISPR Therapeutics from William Blair & Company, where he served as a Partner and Senior Equity Research Analyst covering cell therapy, gene therapy, and gene editing companies. Dr. Prasad succeeds Brendan Smith, who is leaving the Company to pursue external opportunities. "I'm excited to welcome Raju to our leadership team," said Samarth Kulkarni, Ph.D., Chief Exec

    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CRSP
Financials

Live finance-specific insights

See more
  • CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies

    -58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis- -Durable responses in LBCL achieved with six-month CR rate of 21% and longest response on-going at over 18 months after initial infusion- -Response rates and durability are similar to approved autologous CD19 CAR-T therapies on an ITT basis- -Positively differentiated safety profile; no Grade 3 or higher cytokine release syndrome (CRS) and low rates of infection and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)- -Expanding CARBON into a potentially registrational trial in 1Q 20

    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data

    -Management to host conference call and webcast on October 12th at 4:30 p.m. ET- ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that management will host a virtual event on October 12, 2021 at 4:30 p.m. ET to highlight clinical data from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of CTX110, its wholly-owned allogeneic chimeric antigen receptor T cell (CAR-T) investigational therapy targeting CD19, for the treatment of relapsed or refractory B-cell malignancies. Conference Call and Web

    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CRSP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more